Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

TORONTO, ONTARIO--(Marketwired - May 31, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the...
May 18, 2016 17:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting

TORONTO, ONTARIO--(Marketwired - May 18, 2016) - Trillium Therapeutics Inc. (TSX:TR) (NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
May 13, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Reports First Quarter 2016 Financial Results

TORONTO, ONTARIO--(Marketwired - May 13, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical stage immuno-oncology company developing innovative therapies for the...
April 14, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annual Meeting

TORONTO, ONTARIO--(Marketwired - April 14, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer,...
April 12, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium to Present at the 2016 Annual Needham Health Care Conference

TORONTO, ONTARIO--(Marketwired - April 12, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
March 10, 2016 09:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program

TORONTO, ONTARIO--(Marketwired - March 10, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
March 09, 2016 17:30 ET | Source: Trillium Therapeutics Inc.

Trillium Reports 2015 Financial and Operating Results

TORONTO, ONTARIO--(Marketwired - March 9, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
March 08, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium to Present at the Cowen and Company 36th Annual Health Care Conference

TORONTO, ONTARIO--(Marketwired - March 8, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
February 03, 2016 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47

TORONTO, ONTARIO--(Marketwired - Feb. 3, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical stage immuno-oncology company developing innovative therapies for the...
January 27, 2016 08:13 ET | Source: Trillium Therapeutics Inc.

Trillium Acquires Privately-Held Fluorinov Pharma Inc.

TORONTO, ONTARIO--(Marketwired - Jan. 27, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) a clinical immuno-oncology company developing innovative therapies for the treatment of...